Rani Therapeutics Holdings Inc (NASDAQ: RANI) is a clinical-stage biotherapeutics company developing oral drug delivery technology designed to replace injectable biologics. The company does not yet generate product revenue. Its disclosed revenue model centers on license and evaluation agreements with pharmaceutical partners, under which Rani licenses its platform technology. CEO Talat Imran leads the company, with Mir Imran serving as Chairman of the Board. Svai Sanford is Chief Financial Officer. The company files as a smaller reporting company with the SEC, with its 10-K for the fiscal year ended December 31, 2025 filed March 26, 2026. Rani competes against other biotherapeutics and pharmaceutical companies developing alternative drug delivery or injectable biologic platforms. Regulatory approval from the FDA is required before any product candidate can be commercialized, and reimbursement from government and private payors will be required for commercial success.

Revenue model

License and evaluation agreements with pharmaceutical partners. No product revenue disclosed in the filing excerpts provided. Pre-commercial stage as of the fiscal year ended December 31, 2025.

Products and services

Oral drug delivery platform technology (the RaniPill) designed to enable oral administration of biologic therapies that are otherwise injectable. Product candidates are in clinical development. Specific pipeline candidates are not detailed in the provided filing excerpts.

Customers and end markets

Pharmaceutical and biotherapeutic company partners as licensees. End patients are those requiring biologic therapies. Reimbursement from government payors (Medicare, Medicaid) and private health insurers is identified as material to future commercial success.

Value-chain role

Drug delivery platform developer and licensor. Sits upstream of commercialization, providing technology via licensing to pharmaceutical partners. Conducts clinical trials and maintains intellectual property portfolio. Relies on third-party manufacturers and vendors for clinical trial operations.

Geographic exposure

Primarily United States regulatory and commercial focus. Clinical trials conducted in Australia. Data processing activities in Europe and the UK noted in the filing.

Competitors

Unnamed biotherapeutics companies, Unnamed pharmaceutical companies

Source: SEC 10-K, filed 2026-03-26

Industry: Pharmaceutical Preparations Peers: Atea Pharmaceuticals Inc Tvardi Therapeutics Inc Esperion Therapeutics Inc Evolus Inc Fulcrum Therapeutics Inc Ocular Therapeutix Inc Johnson & Johnson Nuvation Bio Inc Phathom Pharmaceuticals Inc Tarsus Pharmaceuticals Inc